StoxEmcure Pharmaceuticals vs Global Health: share price & financials comparison
NSE: EMCURE vs MEDANTA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Emcure Pharmaceuticals vs Global Health at a glance
Emcure Pharmaceuticals (EMCURE) has a market capitalisation of ₹44,804 Cr, against ₹39,065 Cr for Global Health (MEDANTA). Over the past year Emcure Pharmaceuticals has returned +78.3%, compared with +16.4% for Global Health. On valuation, Emcure Pharmaceuticals trades at a lower P/E of 41.0 versus 98.2. Emcure Pharmaceuticals earns a higher return on equity (20.5% vs 9.2%). Emcure Pharmaceuticals comes out ahead on size, valuation, profitability, momentum and technicals. Global Health comes out ahead on financial health. Across the scored metrics below, Emcure Pharmaceuticals leads on 11 and Global Health on 3. On StoxGud's 10-point checklist, Emcure Pharmaceuticals scores 9/10 and Global Health scores 6/10.
| Metric | Emcure Pharmaceuticals | Global Health |
|---|---|---|
| Size | ||
| Market cap | ₹44,804 Cr | ₹39,065 Cr |
| Revenue (latest FY) | ₹9,204 Cr | ₹4,410 Cr |
| Net profit (latest FY) | ₹924 Cr | ₹556 Cr |
| Valuation | ||
| P/E | 41.0 | 98.2 |
| P/B | 8.38 | 9.04 |
| Dividend yield | 0.13% | 0.03% |
| Profitability | ||
| Return on equity | 20.5% | 9.2% |
| Net profit margin | 10.7% | 7.9% |
| Operating margin | 20.4% | 22.1% |
| Growth | ||
| Revenue growth (YoY) | +24.3% | +33.6% |
| Net profit growth (YoY) | +33.7% | -100.0% |
| Revenue CAGR (multi-year) | — | +17.9% |
| Financial health | ||
| Debt to equity | 0.27 | 0.16 |
| Momentum | ||
| 1-month return | +26.4% | +13.6% |
| 1-year return | +78.3% | +16.4% |
| 3-year CAGR | — | +16.9% |
| Distance from 52W high | +0.0% | -3.6% |
| Technicals | ||
| RSI (14) | 94 | 88 |
| Price vs 200-day avg | +34.8% | +15.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Emcure Pharmaceuticals | Global Health |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Emcure Pharmaceuticals or Global Health?
Emcure Pharmaceuticals has a market cap of ₹44,804 Cr and Global Health has a market cap of ₹39,065 Cr as of 13 Nov 2026.
Which has a lower P/E, Emcure Pharmaceuticals or Global Health?
Emcure Pharmaceuticals has the lower P/E: Emcure Pharmaceuticals trades at 41.0 and Global Health at 98.2.
Which gave better returns in the last year, Emcure Pharmaceuticals or Global Health?
Emcure Pharmaceuticals did better: Emcure Pharmaceuticals returned +78.3% and Global Health returned +16.4% over one year.
What is the difference between Emcure Pharmaceuticals and Global Health?
Both are NSE-listed companies in Healthcare. They are about the same size by market cap (₹44,804 Cr vs ₹39,065 Cr). In the latest financial year Emcure Pharmaceuticals reported revenue of ₹9,204 Cr and Global Health ₹4,410 Cr. Operating margin is 20.4% for Emcure Pharmaceuticals and 22.1% for Global Health. Debt to equity is 0.27 for Emcure Pharmaceuticals and 0.16 for Global Health.
Which is better, Emcure Pharmaceuticals or Global Health?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Emcure Pharmaceuticals leads on 11 and Global Health on 3. Emcure Pharmaceuticals is ahead on size, valuation, profitability, momentum and technicals. Global Health is ahead on financial health. On StoxGud's rules-based checklist Emcure Pharmaceuticals scores 9/10 and Global Health scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.